New Gut Drug Prevents Liver Damage After Life-Saving Intestinal Surgery

A groundbreaking new drug could prevent liver failure in patients who undergo life-saving intestinal surgery, addressing a critical gap where no treatments currently exist. When surgeons remove damaged sections of the small intestine due to disease or tissue death, up to 15% of patients later develop serious liver complications, including liver failure requiring transplantation.

Researchers at Washington University School of Medicine developed a gut-targeted compound that protects the liver while improving nutrient absorption. The drug belongs to a class called liver X receptor agonists, which increase production of HDL "good" cholesterol. Unlike previous versions that affected the whole body and caused serious side effects, this new compound works only within the gastrointestinal tract.

In mouse studies, the drug demonstrated remarkable benefits: improved weight gain, reduced harmful liver scarring, and enhanced nutrient absorption. The research builds on earlier findings showing that substances produced by gut bacteria can travel to the liver after surgery and cause damage, while HDL cholesterol helps protect against these harmful compounds.

This breakthrough particularly matters for vulnerable populations like premature infants with necrotizing enterocolitis, who often develop short bowel syndrome after surgery. These patients typically require long-term intravenous feeding, which further strains the liver and increases transplant risk.

While promising, the research remains in early stages with testing only in mice. Human trials will be necessary to confirm safety and effectiveness. However, the gut-restricted approach offers hope for developing the first treatment for a devastating complication that has long lacked therapeutic options.